TKNO Q1 2024 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$133M

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$9M+1.9% YoY

Gross Profit

$2M23.8% margin

Operating Income

-$8M-86.0% margin

Net Income

-$8M-87.2% margin

EPS (Diluted)

$-0.20

QoQ Revenue Growth

+18.1%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$121M

Total Liabilities

$37M

Stockholders' Equity

$83M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$9M	+1.9%
Gross Profit	$2M	$2M	-8.8%
Operating Income	-$8M	-$9M	+10.7%
Net Income	-$8M	-$9M	+8.2%

Revenue Segments

Lab Essentials

$7M78%

Clinical Solutions

$2M18%

Other Product

$306,0003%

Geographic Segments

UNITED STATES

$9M95%

Non-US

$420,0005%